Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.